Ascentage Pharma Group International (NASDAQ:AAPG) Earns “Buy” Rating from BTIG Research

Ascentage Pharma Group International (NASDAQ:AAPG)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a research note issued to investors on Thursday,Benzinga reports. They presently have a $48.00 target price on the stock. BTIG Research’s target price would indicate a potential upside of 124.98% from the stock’s current price.

A number of other analysts have also weighed in on the stock. Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price on the stock. Oppenheimer began coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target for the company. Finally, Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Price Performance

NASDAQ:AAPG opened at $21.34 on Thursday. Ascentage Pharma Group International has a 12-month low of $17.56 and a 12-month high of $48.45. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. The stock has a fifty day moving average price of $24.10 and a 200 day moving average price of $29.99.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million during the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. UBS Group AG raised its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter. XY Capital Ltd boosted its holdings in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares in the last quarter. Tema Etfs LLC purchased a new position in Ascentage Pharma Group International in the second quarter valued at approximately $610,000. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International in the second quarter valued at approximately $391,000. Finally, Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the third quarter worth approximately $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.